Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 82Neoplasms 78Colorectal Neoplasms 67Neoplasm Metastasis 65Prostatic Neoplasms 61Leukemia, Myeloid, Acute 61Ovarian Neoplasms 57Recurrence 55Pancreatic Neoplasms 55Multiple Myeloma 52Melanoma 40Triple Negative Breast Neoplasms 36Lung Neoplasms 36Glioblastoma 36Squamous Cell Carcinoma of Head and Neck 34Endometrial Neoplasms 33Lymphoma, Non-Hodgkin 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Lymphoma, Large B-Cell, Diffuse 28Carcinoma, Renal Cell 28Lymphoma 27Stomach Neoplasms 26Small Cell Lung Carcinoma 26Carcinoma, Hepatocellular 26Myelodysplastic Syndromes 25Lymphoma, B-Cell 25Advanced Solid Tumor 25Leukemia, Lymphocytic, Chronic, B-Cell 24Brain Neoplasms 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Microsatellite Instability × 90 days × Clear all
NCT06898450 2026-05-06

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Nimbus Therapeutics

Phase 1/2 Recruiting
134 enrolled

Werner Syndrome, Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡